Utilized for benign prostatic hyperplasia to manage prostate volume and support urinary flow improvement.
Mechanism of Action
Finasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) by blocking the 5-alpha reductase enzyme. Lowering DHT levels leads to regression of prostatic tissue.
Route of Administration
Oral
Onset Time
3–6 months
Duration
24 hours
Contraindications
Pregnancy, Hypersensitivity to finasteride, Use in females
Severe Adverse Events
Prostate cancer (high-grade), Depression, Male breast cancer — requires immediate medical attention
Common Side Effects
Erectile dysfunction, Decreased libido, Nausea
Uncommon Side Effects
Breast enlargement, Rash, Abdominal pain
Drug Interactions
Alcohol
Pregnancy Safety Warnings
FDA Category X: Contraindicated. Pregnant women must not handle crushed tablets. Breastfeeding: Not applicable.
Information related to Fincar is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
